Results 111 to 120 of about 3,591 (213)

A phase IIb randomized, chronic-dosing, incomplete block, cross-over study of glycopyrronium, delivered via metered dose inhaler, compared with a placebo and an active control in patients with moderate-to-severe COPD

Respiratory Research, 2018
Background Long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) bronchodilators are key to the pharmacologic treatment of chronic obstructive pulmonary disease (COPD).
Edward M. Kerwin, Selwyn Spangenthal, Christine Kollar, Earl St Rose, Colin Reisner   +4 more
doaj   +1 more source

Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways

Respiratory Research, 2018
Background Corticosteroids increase the expression of β2-adrenoceptors (β2-ARs) and protect them against down-regulation. Conversely, β2-AR agonists improve the anti-inflammatory action of corticosteroids.
Luigino Calzetta, Maria Gabriella Matera, Francesco Facciolo, Mario Cazzola, Paola Rogliani   +4 more
doaj   +1 more source

DEVELOPMENT AND VALIDATION OF STABILITY INDICATING RP-HPLC METHOD FOR THE SIMULTANEOUS ESTIMATION OF ACLIDINIUM BROMIDE AND FORMOTEROL FUMARATE IN BULK AND INHALER FORMULATION [PDF]

, 2022
Objective: To develop a simple, accurate, precise, rapid and sensitive method for the simultaneous estimation of Formoterol fumarate and Aclidinium bromide in pharmaceutical dosage form. Methods: The chromatogram was run through Ascentis C18 150 x 4.6 mm,
ABHISHEK, K., ASHRITHA, N., BALAJI, P. V., LAKSHMI, A. JAYA, PRIYANKA, Y. LEELA   +4 more
core   +1 more source

Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD

International Journal of COPD, 2019
Masakazu Ichinose,1 Yasushi Fukushima,2 Yoshikazu Inoue,3 Osamu Hataji,4 Gary T Ferguson,5 Klaus F Rabe,6 Nobuya Hayashi,7 Hiroshi Okada,7 Mami Takikawa,7 Eric Bourne,8 Shaila Ballal,9 Kiernan DeAngelis,10 Magnus Aurivillius,11 Colin Reisner,9 Paul ...
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P   +14 more
doaj  

FUNCTIONAL RESPIRATORY IMAGING ASSESSMENT OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE AND GLYCOPYRROLATE/FORMOTEROL FUMARATE METERED DOSE INHALERS IN PATIENTS WITH COPD [PDF]

Chest, 2020
M. van den Berge, Jan De Backer, Cedric Van Holsbeke, Wilfried De Backer, Roopa Trivedi, Martin Jenkins, Paul Dorinsky, Magnus Aurivillius   +7 more
openaire   +1 more source

Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD

International Journal of COPD, 2018
Edward M Kerwin,1 Thomas M Siler,2 Samir Arora,3 Patrick Darken,4 Earl St Rose,4 Colin Reisner4,5 1Clinical Research Institute of Southern Oregon, Medford, OR, USA; 2Midwest Chest Consultants, St Charles, MO, USA; 3Aventiv Research, Columbus, OH, USA ...
Kerwin EM, Siler TM, Arora S, Darken P, St Rose E, Reisner C   +5 more
doaj  

Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease

Frontiers in Medicine
IntroductionMonoclonal antibodies (mAbs) against cytokines and chemokines or their receptors promise to be a potential therapeutic option to address chronic obstructive pulmonary disease (COPD).
Yu Xiong, Yu Xiong, Yu Xiong, Jia-qiang Hu, Hui-lin Tang, Zhi-xia Zhao, Zhi-xia Zhao, Li-hong Liu, Li-hong Liu   +8 more
doaj   +1 more source

Formoterol Dry-Powder Inhalation ??? Novartis/SkyePharma

Drugs in R & D, 2004
In November 1998, Novartis Pharma of Switzerland and SkyePharma PLC of the UK signed an agreement to jointly develop a new formulation of the beta(2)-adrenoceptor agonist formoterol (Foradil). The new product, Foradil Certihaler, utilises a multidose dry-powder inhaler (MDPI or MDDPI) device, SkyeHaler, developed by SkyePharma.
openaire   +2 more sources

Budesonide/Formoterol Easyhaler: Performance Under Simulated Real-Life Conditions [PDF]

, 2017

core   +1 more source

Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap

International Journal of COPD, 2020
Yoshihisa Ishiura,1,2 Masaki Fujimura,3 Noriyuki Ohkura,4 Johsuke Hara,4 Kazuo Kasahara,4 Nobuyasu Ishii,1 Yusuke Sawai,1 Toshiki Shimizu,1 Takeshi Tamaki,1 Shosaku Nomura1 1First Department of Internal Medicine, Kansai Medical University, Moriguchi ...
Ishiura Y, Fujimura M, Ohkura N, Hara J, Kasahara K, Ishii N, Sawai Y, Shimizu T, Tamaki T, Nomura S   +9 more
doaj